 Nidhya Navanandan
Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 11 | 2024 | 2066 | 2.970 |
Why?
| | Anti-Asthmatic Agents | 4 | 2024 | 350 | 1.740 |
Why?
| | Pneumonia | 7 | 2023 | 576 | 1.460 |
Why?
| | Respiratory Tract Infections | 3 | 2023 | 323 | 0.960 |
Why?
| | Community-Acquired Infections | 5 | 2023 | 141 | 0.940 |
Why?
| | Emergency Service, Hospital | 10 | 2024 | 1829 | 0.920 |
Why?
| | Virus Diseases | 2 | 2023 | 200 | 0.830 |
Why?
| | Child | 22 | 2024 | 18486 | 0.730 |
Why?
| | Airway Resistance | 1 | 2020 | 33 | 0.720 |
Why?
| | Oscillometry | 1 | 2020 | 33 | 0.710 |
Why?
| | Staphylococcus aureus | 1 | 2023 | 385 | 0.690 |
Why?
| | Glucocorticoids | 2 | 2020 | 552 | 0.610 |
Why?
| | Biomedical Research | 1 | 2023 | 588 | 0.580 |
Why?
| | Patient Discharge Summaries | 1 | 2017 | 10 | 0.570 |
Why?
| | Physicians, Primary Care | 1 | 2020 | 222 | 0.560 |
Why?
| | Pulmonary Embolism | 1 | 2019 | 182 | 0.550 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 68 | 0.550 |
Why?
| | Dexamethasone | 3 | 2024 | 316 | 0.500 |
Why?
| | Health Literacy | 1 | 2017 | 166 | 0.480 |
Why?
| | Physicians | 1 | 2022 | 776 | 0.470 |
Why?
| | Prednisone | 3 | 2020 | 232 | 0.470 |
Why?
| | Emergency Medical Services | 2 | 2021 | 590 | 0.450 |
Why?
| | Acute Disease | 4 | 2024 | 914 | 0.400 |
Why?
| | Patient Readmission | 1 | 2017 | 609 | 0.390 |
Why?
| | Caregivers | 1 | 2017 | 716 | 0.350 |
Why?
| | Prednisolone | 2 | 2020 | 77 | 0.350 |
Why?
| | Child, Preschool | 8 | 2024 | 9130 | 0.350 |
Why?
| | Prospective Studies | 9 | 2024 | 6264 | 0.330 |
Why?
| | Humans | 23 | 2024 | 115612 | 0.330 |
Why?
| | Adrenal Cortex Hormones | 2 | 2023 | 509 | 0.310 |
Why?
| | Patient Discharge | 3 | 2024 | 770 | 0.280 |
Why?
| | Hospitalization | 4 | 2022 | 1765 | 0.260 |
Why?
| | Quality of Life | 4 | 2024 | 2387 | 0.240 |
Why?
| | Severity of Illness Index | 3 | 2022 | 2578 | 0.230 |
Why?
| | Enterotoxins | 1 | 2023 | 88 | 0.220 |
Why?
| | Male | 10 | 2024 | 55967 | 0.210 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 60 | 0.210 |
Why?
| | Delphi Technique | 1 | 2023 | 164 | 0.200 |
Why?
| | Viruses | 1 | 2023 | 94 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 97 | 0.200 |
Why?
| | Magnesium | 1 | 2022 | 145 | 0.200 |
Why?
| | Administration, Intravenous | 1 | 2022 | 126 | 0.190 |
Why?
| | Dyspnea | 1 | 2023 | 223 | 0.190 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 4668 | 0.190 |
Why?
| | Consensus | 1 | 2023 | 532 | 0.180 |
Why?
| | Allergens | 1 | 2023 | 418 | 0.170 |
Why?
| | Bronchodilator Agents | 2 | 2021 | 249 | 0.160 |
Why?
| | Medication Adherence | 1 | 2024 | 538 | 0.160 |
Why?
| | Thrombectomy | 1 | 2019 | 53 | 0.160 |
Why?
| | Self Report | 1 | 2022 | 698 | 0.160 |
Why?
| | Risk Factors | 3 | 2022 | 8699 | 0.160 |
Why?
| | Administration, Oral | 1 | 2020 | 734 | 0.160 |
Why?
| | Vena Cava Filters | 1 | 2019 | 50 | 0.160 |
Why?
| | Influenza, Human | 1 | 2023 | 548 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2020 | 741 | 0.150 |
Why?
| | Ipratropium | 1 | 2017 | 6 | 0.140 |
Why?
| | Female | 8 | 2024 | 59931 | 0.140 |
Why?
| | Nebulizers and Vaporizers | 1 | 2017 | 80 | 0.140 |
Why?
| | Albuterol | 1 | 2017 | 105 | 0.140 |
Why?
| | Sepsis | 1 | 2022 | 515 | 0.140 |
Why?
| | Single-Blind Method | 1 | 2017 | 255 | 0.130 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 127 | 0.130 |
Why?
| | Phenotype | 1 | 2023 | 2831 | 0.130 |
Why?
| | Prognosis | 1 | 2023 | 3339 | 0.130 |
Why?
| | Health Surveys | 1 | 2017 | 446 | 0.120 |
Why?
| | Anticoagulants | 1 | 2019 | 549 | 0.120 |
Why?
| | Infant | 4 | 2023 | 7975 | 0.120 |
Why?
| | Disease Progression | 1 | 2021 | 2418 | 0.120 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1127 | 0.110 |
Why?
| | Ambulatory Care | 1 | 2017 | 479 | 0.110 |
Why?
| | Biomarkers | 1 | 2023 | 3467 | 0.110 |
Why?
| | Patient Satisfaction | 1 | 2017 | 585 | 0.110 |
Why?
| | Primary Health Care | 1 | 2020 | 1518 | 0.090 |
Why?
| | Pediatrics | 1 | 2017 | 986 | 0.080 |
Why?
| | Adolescent | 3 | 2024 | 17903 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1200 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2021 | 12608 | 0.070 |
Why?
| | Adult | 2 | 2020 | 30726 | 0.070 |
Why?
| | Anti-Bacterial Agents | 2 | 2022 | 1485 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 42 | 0.050 |
Why?
| | Treatment Failure | 1 | 2024 | 332 | 0.050 |
Why?
| | Young Adult | 1 | 2017 | 10487 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2022 | 5059 | 0.050 |
Why?
| | Fever | 1 | 2022 | 280 | 0.050 |
Why?
| | Aftercare | 1 | 2022 | 187 | 0.050 |
Why?
| | ROC Curve | 1 | 2022 | 451 | 0.050 |
Why?
| | Fatigue | 1 | 2022 | 296 | 0.050 |
Why?
| | Epinephrine | 1 | 2021 | 167 | 0.040 |
Why?
| | Middle Aged | 1 | 2020 | 27014 | 0.040 |
Why?
| | Odds Ratio | 1 | 2022 | 962 | 0.040 |
Why?
| | Hospitals, Pediatric | 1 | 2022 | 478 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2022 | 4440 | 0.030 |
Why?
| | Cohort Studies | 1 | 2022 | 4945 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 4438 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2024 | 9159 | 0.020 |
Why?
| | United States | 1 | 2022 | 12297 | 0.020 |
Why?
|
|
Navanandan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|